Furthermore, alternatives such as HER2 targeting in cisplatin-resistant tumors is an ongoing and exciting area of investigation, given that HER2 over-expression has been linked to poor survival in penile squamous cell carcinoma with an immunohistochemical expression rate of approximately 47.7% [132]. The gene discussed is ERBB2; the disease is squamous cell carcinoma of penis.